

# UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED JUNE 30, 2009

## AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas VasANJI Road,  
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 30.06.2009 (Unaudited)	Quarter ended 30.06.2008 (Unaudited)	Half year ended 30.06.2009 (Unaudited)	Half year ended 30.06.2008 (Unaudited)	Year 30.06.2008 (Audited)
<b>1 (a) Net Sales</b>	2,499	2,486	4,788	4,655	9,832
<b>(b) Other Operating income</b>	169	118	395	230	532
<b>Total</b>	2,668	2,604	5,183	4,885	10,364
<b>2 Expenditure</b>					
<b>(a) (Increase) / Decrease in stock in trade and work in progress</b>	(68)	59	(209)	129	104
<b>(b) Consumption of raw materials</b>	968	753	1,915	1,306	3,071
<b>(c) Purchase of traded goods</b>	297	362	601	773	1,580
<b>(d) Employees cost</b>	352	294	678	577	1,199
<b>(e) Depreciation</b>	43	44	85	95	182
<b>(f) Other expenditure</b>	421	514	884	961	2,020
<b>(g) Total</b>	2,013	2,026	3,954	3,841	8,166

Particulars	Quarter ended 30.06.2009 (Unaudited)	Quarter ended 30.06.2008 (Unaudited)	Half year ended 30.06.2009 (Unaudited)	Half year ended 30.06.2008 (Unaudited)	Year ended 30.06.2009 (Unaudited)
<b>3 Profit from Operation before Other income and Interest(1-2)</b>	655	578	1,229	1,044	2,200
<b>4 Other Income</b>	80	78	174	155	394
<b>5 Profit before Interest (3+4)</b>	735	656	1,403	1,199	2,594
<b>6 Interest</b>	-	-	-	-	3
<b>7 Profit before tax(5-6)</b>	735	656	1,403	1,199	2,597
<b>8 Tax expense</b>	264	238	527	436	934
<b>9 Net Profit for the period (7-8)</b>	471	418	876	763	1,663
<b>10 Paid-up equity share capital (Face Value of Rs. 10 per share)</b>	230	230	230	230	230
<b>11 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	-	-	7,880
<b>12 Earnings Per Share (EPS) (Rs.)</b>					
<b>Basic and diluted EPS for the period, for the year to date and for the previous year</b>	20.48	18.17	38.09	33.17	72.10
<b>13 Public Shareholding</b>					
<b>- Number of Shares</b>	9,120,955	9,120,955	9,120,955	9,120,955	9,120,955
<b>- Percentage of Shareholding</b>	39.60	39.60	39.60	39.60	39.60

Particulars	Quarter ended 30.06.2009 (Unaudited)	Quarter ended 30.06.2008 (Unaudited)	Half year ended 30.06.2009 (Unaudited)	Half year ended 30.06.2008 (Unaudited)	Year ended 30.06.2009 (Unaudited)
<b>14 Promoters and Promoter group Shareholding</b>					
<b>a) Pledged/Encumbered</b>					
- Number of Shares	2,365,920		2,365,920		
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	17.01%		17.01%		
- Percentage of shares (as a % of total share capital of the company)	10.27%		10.27%		
<b>b) Non-encumbered</b>					
- Number of Shares	11,543,747		11,543,747		
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	82.99%		82.99%		
- Percentage of shares (as a % of total share capital of the company)	50.13%		50.13%		

## Notes:

- The above results were approved by the Board of Directors of the Company at its Meeting held on July 22, 2009.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the half year ended June 30, 2009.

- The Company discontinued the distribution of the anti-rabies vaccine, Rabipur from February 19, 2009, pursuant to the Award of the Arbitrator in the matter relating to the disputes between the Company, Novartis Vaccines and Diagnostics Inc. and Chiron Behring Vaccines Private Limited (CBVPL) regarding the non-renewal of the Distribution Agreement for Rabipur. The Company continues to hold 49% of the share capital of CBVPL.
- The break up of Net Sales is as follows:

### Rs Million

Particulars	Quarter ended June 30, 2009	Quarter ended June 30, 2008	Growth %	Half year ended June 30, 2009	Half year ended June 30, 2008	Growth %
<b>Domestic Sales- Others</b>	1,888	1,679	12.4%	3,509	3,093	13.4%
<b>Domestic Sales- Rabipur</b>	-	309	-100.0%	92	670	-86.3%
<b>Export Sales</b>	611	498	22.7%	1,187	892	33.1%
<b>Total Sales</b>	<b>2,499</b>	<b>2,486</b>	<b>0.5%</b>	<b>4,788</b>	<b>4,655</b>	<b>2.8%</b>

Excluding the impact of discontinuation of Rabipur distribution, comparable sales growth would have been 14.8% for the quarter and 17.8% for the half-year ended June 30, 2009.

- The Company has a single business segment namely 'Pharmaceutical Business'.
- The Board of Directors has declared an Interim Dividend of Rs 3.50 per Equity share of Rs 10 to be paid to those Members whose names appear on the Register of Members of the Company on July 31, 2009 being the Record Date.
- Information on investor complaints is furnished below:

Pending as on April 1, 2009	Received during the quarter	Disposed of during the quarter	Pending as on June 30, 2009
Nil	7	7	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

**AVENTIS PHARMA LIMITED**  
**DR. SHAILESH AYYANGAR**  
**MANAGING DIRECTOR**